The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Bioconjugate Chemistry · 15.11.2023 · 34 (11) · 1951-2000
DOI: 10.1021/acs.bioconjchem.3c00374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, online erschienen am 11.10.2023. Verfasst von Janet M Sasso und 6 weiteren Autor:innen. Beteiligte Einrichtung: CAS, A Division of the American Chemical Society, Columbus, Ohio 43210, United States. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 543 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently among the most promising drug classes in oncology, with efforts to expand their application for nononcological indications and in combination therapies. Here we provide a detailed overview of the recent advances in ADC research and consider future directions and challenges in promoting this promising platform to widespread therapeutic use. We examine data from the CAS Content Collection, the largest human-curated collection of published scientific information, and analyze the publication landscape of recent research to reveal the exploration trends in published documents and to provide insights into the scientific advances in the area. We also discuss the evolution of the key concepts in the field, the major technologies, and their development pipelines with company research focuses, disease targets, development stages, and publication and investment trends. A comprehensive concept map has been created based on the documents in the CAS Content Collection. We hope that this report can serve as a useful resource for understanding the current state of knowledge in the field of ADCs and the remaining challenges to fulfill their potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CAS, A Division of the American Chemical Society, Columbus, Ohio 43210, United States.
- ACS International India Pvt. Ltd., Pune 411044, India.
ORCID-Profile: Janet M Sasso, Rumiana Tenchov, Robert Bird, Qiongqiong Angela Zhou
Zitieren
APA
Sasso, J. M., Tenchov, R., Bird, R., Iyer, K. A., Ralhan, K., Rodriguez, Y., & Zhou, Q. A. (2023). The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress. Bioconjugate Chemistry, 34(11), 1951-2000. https://doi.org/10.1021/acs.bioconjchem.3c00374
Vancouver
Sasso JM, Tenchov R, Bird R, Iyer KA, Ralhan K, Rodriguez Y, et al. The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress. Bioconjugate Chemistry. 2023;34(11):1951-2000. doi:10.1021/acs.bioconjchem.3c00374
BibTeX
@article{Sasso2023,
author = {Sasso, Janet M and Tenchov, Rumiana and Bird, Robert and Iyer, Kavita A and Ralhan, Krittika and Rodriguez, Yacidzohara and Zhou, Qiongqiong Angela},
title = {The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress},
journal = {Bioconjugate Chemistry},
year = {2023},
volume = {34},
number = {11},
pages = {1951--2000},
doi = {10.1021/acs.bioconjchem.3c00374}
}
EUVIMED